Increasing the effectiveness of hematopoiesis in myelodysplastic syndromes: erythropoiesis-stimulating agents and transforming growth factor-β superfamily inhibitors

Seminars in Hematology

Volumn 54, Issue 3, 2017, Pages 141-146

  Mies, Anna ^a   Platzbecker, Uwe ^a  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

Author keywords

ESA; lower risk MDS; Luspatercept; Sotatercept; TGF

Indexed keywords

ACTIVIN RECEPTOR 2; ANTIANEMIC AGENT; LENALIDOMIDE; LUSPATERCEPT; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PLACEBO; RECOMBINANT ERYTHROPOIETIN; SOTATERCEPT; TRANSFORMING GROWTH FACTOR BETA; INHIBIN;

ANEMIA; CELL DIFFERENTIATION; CELL PROLIFERATION; CLINICAL TRIAL (TOPIC); DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; DRUG TREATMENT FAILURE; ERYTHROCYTE; ERYTHROPOIESIS; FATIGUE; HEMATOPOIESIS; HUMAN; IRON OVERLOAD; MYELODYSPLASTIC SYNDROME; NONHUMAN; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SIGNAL TRANSDUCTION; GENETICS;

HEMATINICS; HEMATOPOIESIS; HUMANS; INHIBIN-BETA SUBUNITS; MYELODYSPLASTIC SYNDROMES; TRANSFORMING GROWTH FACTOR BETA;

EID: 85026524940     PISSN: 00371963     EISSN: 15328686     Source Type: Journal    
DOI: 10.1053/j.seminhematol.2017.06.004     Document Type: Review

References (61)

1. Fenaux, P., Ades, L., How we treat lower-risk myelodysplastic syndromes. Blood 121:21 (2013), 4280–4286.
2. Anand, I., McMurray, J.J.V., Whitmore, J., et al. Anemia and its relationship to clinical outcome in heart failure. Circulation 110:2 (2004), 149–154.
3. Shander, A., Cappellini, M.D., Goodnough, L.T., Iron overload and toxicity: The hidden risk of multiple blood transfusions. Vox Sanguinis, 2009, 185–197.
4. Almeida, A., Fenaux, P., List, A.F., Raza, A., Platzbecker, U., Santini, V., Recent advances in the treatment of lower-risk non-del(5q) myelodysplastic syndromes (MDS). Leuk Res 52 (2017), 50–57.
5. Hellström-Lindberg, E., Efficacy of erythropoietin in the myelodysplastic syndromes: a meta-analysis of 205 patients from 17 studies. Br J Haematol 89:1 (1995), 67–71.
6. Stasi, R., Brunetti, M., Bussa, S., et al. Response to recombinant human erythropoietin in patients with myelodysplastic syndromes. Clin Cancer Res 3:5 (1997), 733–739.
7. Ferrini, P.R., Grossi, A., Vannucchi, A.M., et al. A randomized double-blind placebo-controlled study with subcutaneous recombinant human erythropoietin in patients with low-risk myelodysplastic syndromes. Br J Haematol 103:4 (1998), 1070–1074.
8. Terpos, E., Mougiou, A., Kouraklis, A., et al. Prolonged administration of erythropoietin increases erythroid response rate in myelodysplastic syndromes: a phase ii trial in 281 patients. Br J Haematol 118:1 (2002), 174–180.
9. Fenaux, P., Santini, V., Spiriti, M.A.A., et al. Randomized, double-blind, placebo-controlled, multicenter study evaluating epoetin alfa versus placebo in anemic patients with IPSS LOW- INT1 risk MDS. Haematologica, 2016, P248.
10. Stasi, R., Abruzzese, E., Lanzetta, G., Terzoli, E., Amadori, S., Darbepoetin alfa for the treatment of anemic patients with low- and intermediate-1-risk myelodysplastic syndromes. Ann Oncol 16:12 (2005), 1921–1927.
11. Mannone, L., Gardin, C., Quarre, M.C., et al. High-dose darbepoetin alpha in the treatment of anaemia of lower risk myelodysplastic syndrome results of a phase II study. Br J Haematol 133:5 (2006), 513–519.
12. Gabrilove, J., Paquette, R., Lyons, R.M., et al. Phase 2, single-arm trial to evaluate the effectiveness of darbepoetin alfa for correcting anaemia in patients with myelodysplastic syndromes. Br J Haematol 142:3 (2008), 379–393.
13. Park, S., Fenaux, P., Greenberg, P., et al. Efficacy and safety of darbepoetin alpha in patients with myelodysplastic syndromes: a systematic review and meta-analysis. Br J Haematol 174:5 (2016), 730–747.
14. Platzbecker, U., Symeonidis, A., Oliva, E.N., et al. A phase 3 randomized placebo-controlled trial of darbepoetin alfa in patients with anemia and lower-risk myelodysplastic syndromes. Leukemia, 2017 Jun 19 (epub ahead of print).
15. Santini, V., Schemenau, J., Levis, A., et al. Can the revised IPSS predict response to erythropoietic-stimulating agents in patients with classical IPSS low or intermediate-1 MDS?. Blood 122:13 (2013), 2286–2288.
16. Garelius, H.K., Johnston, W.T., Smith, A.G., et al. Erythropoiesis-stimulating agents significantly delay the onset of a regular transfusion need in nontransfused patients with lower-risk myelodysplastic syndrome. J Intern Med. 281:3 (2017), 284–299.
17. Park, S., Kelaidi, C., Sapena, R., et al. Early introduction of ESA in low risk MDS patients may delay the need for RBC transfusion: a retrospective analysis on 112 patients. Leuk Res 34:11 (2010), 1430–1436.
18. Moyo, V., Lefebvre, P., Duh, M.S., Yektashenas, B., Mundle, S., Erythropoiesis-stimulating agents in the treatment of anemia in myelodysplastic syndromes: a meta-analysis. Ann Hematol, 2008, 527–536.
19. Frisan, E., Pawlikowska, P., Pierre-Eugène, C., et al. p-ERK1/2 is a predictive factor of response to erythropoiesis-stimulating agents in low/int-1 myelodysplastic syndromes. Haematologica 95:11 (2010), 1964–1968.
20. Spinelli, E., Caporale, R., Buchi, F., et al. Distinct signal transduction abnormalities and erythropoietin response in bone marrow hematopoietic cell subpopulations of myelodysplastic syndrome patients. Clin Cancer Res 18:11 (2012), 3079–3089.
21. Kosmider, O., Passet, M., Santini, V., et al. Are somatic mutations predictive of response to erythropoiesis stimulating agents in lower risk myelodysplastic syndromes?. Haematologica 101:7 (2016), e280–e283.
22. Jädersten, M., Dybedal, I., Della Porta, M.G., et al. Erythropoietin and granulocyte-colony stimulating factor treatment associated with improved survival in myelodysplastic syndrome. J Clin Oncol 26 (2008), 3607–3613.
23. Park, S., Grabar, S., Kelaidi, C., et al. Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF: the GFM experience. Blood 111:2 (2008), 574–582.
24. Greenberg, P.L., Sun, Z., Miller, K.B., et al. Treatment of myelodysplastic syndrome patients with erythropoietin with or without granulocyte colony-stimulating factor: results of a prospective randomized phase 3 trial by the Eastern Cooperative Oncology Group (E1996). Blood 114:12 (2009), 2393–2400.
25. Mundle, S., Lefebvre, P., Vekeman, F., Duh, M.S., Rastogi, R., Moyo, V., An assessment of erythroid response to epoetin alpha as a single agent versus in combination with granulocyte- or granulocyte-macrophage-colony-stimulating factor in myelodysplastic syndromes using a meta-analysis approach. Cancer 115:4 (2009), 706–715.
26. Kelaidi, C., Park, S., Brechignac, S., et al. Treatment of myelodysplastic syndromes with 5q deletion before the lenalidomide era; the GFM experience with EPO and thalidomide. Leuk Res 32:7 (2008), 1049–1053.
27. Fenaux, P., Giagounidis, A., Selleslag, D., et al. A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q. Blood 118:14 (2011), 3765–3776.
28. Kelaidi, C., Park, S., Sapena, R., et al. Long-term outcome of anemic lower-risk myelodysplastic syndromes without 5q deletion refractory to or relapsing after erythropoiesis-stimulating agents. Leukemia 27:6 (2013), 1283–1290.
29. Park, S., Hamel, J.F., Toma, A., et al. Outcome of Lower-Risk Patients With Myelodysplastic Syndromes Without 5q Deletion After Failure of Erythropoiesis-Stimulating Agents. J Clin Oncol. 35:14 (2017), 1591–1597.
30. Tobiasson, M., Dybedahl, I., Holm, M.S., et al. Limited clinical efficacy of azacitidine in transfusion-dependent, growth factor-resistant, low- and Int-1-risk MDS: Results from the nordic NMDSG08A phase II trial. Blood Cancer J, 4(3), 2014, e189.
31. Raza, A., Reeves, J.A., Feldman, E.J., et al. Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1-risk myelodysplastic syndromes with karyotypes other than deletion 5q. Blood 111:1 (2008), 86–93.
32. List, A., Kurtin, S., Roe, D.J., et al. Efficacy of lenalidomide in myelodysplastic syndromes. N Engl J Med 352:6 (2005), 549–557.
33. Komrokji, R.S., Lancet, J.E., Swern, A.S., et al. Combined treatment with lenalidomide and epoetin alfa in lower-risk patients with myelodysplastic syndrome. Blood 120:17 (2012), 3419–3424.
34. Sibon, D., Cannas, G., Baracco, F., et al. Lenalidomide in lower-risk myelodysplastic syndromes with karyotypes other than deletion 5q and refractory to erythropoiesis-stimulating agents. Br J Haematol 156:5 (2012), 619–625.
35. Toma, A., Kosmider, O., Chevret, S., et al. Lenalidomide with or without erythropoietin in transfusion-dependent erythropoiesis-stimulating agent-refractory lower-risk MDS without 5q deletion. Leukemia 30:4 (2016), 897–905.
36. Aul, C., Arning, M., Runde, V., Schneider, W., Serum erythropoietin concentrations in patients with myelodysplastic syndromes. Leuk Res 15:7 (1991), 571–575.
37. Hattangadi, S.M., Wong, P., Zhang, L., Flygare, J., Lodish, H.F., From stem cell to red cell: regulation of erythropoiesis at multiple levels by multiple proteins, RNAs, and chromatin modifications. Blood 118:24 (2011), 6258–6268.
38. Claessens, Y.E., Bouscary, D., Dupont, J.M., et al. In vitro proliferation and differentiation of erythroid progenitors from patients with myelodysplastic syndromes: Evidence for Fas-dependent apoptosis. Blood 99:5 (2002), 1594–1601.
39. Zermati, Y., Fichelson, S., Valensi, F., et al. Transforming growth factor inhibits erythropoiesis by blocking proliferation and accelerating differentiation of erythroid progenitors. Exp Hematol 28:8 (2000), 885–894.
40. Xie, Y., Bai, H., Liu, Y., Hoyle, D.L., Cheng, T., Wang, Z.Z., Cooperative effect of erythropoietin and TGF-β inhibition on erythroid development in human pluripotent stem cells. J Cell Biochem 116:12 (2015), 2735–2743.
41. Blank, U., Karlsson, S., TGF-β signaling in the control of hematopoietic stem cells. Blood 125:23 (2015), 3542–3550.
42. Suragani, R.N.V.S., Cadena, S.M., Cawley, S.M., et al. Transforming growth factor-β superfamily ligand trap ACE-536 corrects anemia by promoting late-stage erythropoiesis. Nat Med 20:4 (2014), 408–414.
43. Zhou, L., Nguyen, A.N., Sohal, D., et al. Inhibition of the TGF-β receptor I kinase promotes hematopoiesis in MDS. Blood 112:8 (2008), 3434–3443.
44. Bhagat, T.D., Zhou, L., Sokol, L., et al. MiR-21 mediates hematopoietic suppression in MDS by activating TGF-β signaling. Blood 121:15 (2013), 2875–2881.
45. Zhou, L., McMahon, C., Bhagat, T., et al. Reduced SMAD7 leads to overactivation of TGF-β signaling in MDS that can be reversed by a specific inhibitor of TGF-β receptor I kinase. Cancer Res 71:3 (2011), 955–963.
46. Raje, N., Vallet, S., Sotatercept, a soluble activin receptor type 2A IgG-Fc fusion protein for the treatment of anemia and bone loss. Curr Opin Mol Ther 12:5 (2010), 586–597.
47. Lotinun, S., Pearsall, R.S., Davies, M.V., et al. A soluble activin receptor Type IIA fusion protein (ACE-011) increases bone mass via a dual anabolic-antiresorptive effect in Cynomolgus monkeys. Bone 46:4 (2010), 1082–1088.
48. Fajardo, R.J., Manoharan, R.K., Pearsall, R.S., et al. Treatment with a soluble receptor for activin improves bone mass and structure in the axial and appendicular skeleton of female cynomolgus macaques (Macaca fascicularis). Bone 46:1 (2010), 64–71.
49. Pearsall, R.S., Canalis, E., Cornwall-Brady, M., et al. A soluble activin type IIA receptor induces bone formation and improves skeletal integrity. Proc Natl Acad Sci U S A 105:19 (2008), 7082–7087.
50. Mulivor, A.W., Barbosa, D., Kumar, R., Sherman, M.L., Seehra, J.S., Pearsall, R.S., RAP-011, a soluble activin receptor type IIa murine IgG-Fc fusion protein, prevents chemotherapy induced anemia. Blood, 114(22), 2009, 161.
51. Dussiot, M., Maciel, T.T., Fricot, A., et al. An activin receptor IIA ligand trap corrects ineffective erythropoiesis in β-thalassemia. Nat Med 20:4 (2014), 398–407.
52. Carrancio, S., Markovics, J., Wong, P., et al. An activin receptor IIA ligand trap promotes erythropoiesis resulting in a rapid induction of red blood cells and haemoglobin. Br J Haematol 165:6 (2014), 870–882.
53. Ruckle, J., Jacobs, M., Kramer, W., et al. Single-dose, randomized, double-blind, placebo-controlled study of ACE-011 (ActRIIA-IgG1) in postmenopausal women. J Bone Miner Res 24:4 (2009), 744–752.
54. Sherman, M.L., Borgstein, N.G., Mook, L., et al. Multiple-dose, safety, pharmacokinetic, and pharmacodynamic study of sotatercept (ActRIIA-IgG1), a novel erythropoietic agent, in healthy postmenopausal women. J Clin Pharmacol 53:11 (2013), 1121–1130.
55. Abdulkadyrov, K.M., Salogub, G.N., Khuazheva, N.K., et al. Sotatercept in patients with osteolytic lesions of multiple myeloma. Br J Haematol 165:6 (2014), 814–823.
56. Iancu-Rubin, C., Mosoyan, G., Wang, J., Kraus, T., Sung, V., Hoffman, R., Stromal cell-mediated inhibition of erythropoiesis can be attenuated by Sotatercept (ACE-011), an activin receptor type II ligand trap. Exp Hematol 41:2 (2013), 155–166 e17.
57. Komrokji, R.S., Garcia-Manero, G., Ades, L., et al. An open-label, phase 2, dose-finding study of sotatercept (ACE-011) in patients with low or intermediate-1 (int-1) myelodysplastic syndromes (MDS) or non-proliferative chronic myelomonocytic leukemia (CMML) and anemia requiring transfusion. Blood, 124(21), 2014, 3251.
58. Attie, K.M., Allison, M.J., Mcclure, T., et al. A phase 1 study of ACE-536, a regulator of erythroid differentiation, in healthy volunteers. Am J Hematol 89:7 (2014), 766–770.
59. Platzbecker, U., Germing, U., Götze, K., et al. Luspatercept increases hemoglobin and reduces transfusion burden in patients with low-intermediate risk myelodysplastic syndromes (MDS): long-term results from phase 2 PACE-MDS study. Blood, 128(22), 2016, 3168.
60. Piga, A., Perrotta, S., Gamberini, M.R., et al. Luspatercept (ACE-536) reduces disease burden, including anemia, iron overload, and leg ulcers, in adults with beta-thalassemia: results from a phase 2 study. Blood, 126(23), 2015, 752.
61. Mies, A., Hermine, O., Platzbecker, U., Activin receptor II ligand traps and their therapeutic potential in myelodysplastic syndromes with ring sideroblasts. Curr Hematol Malig Rep 11:6 (2016), 416–424.